Zivo Bioscience, Inc.

Name: Zivo Bioscience, Inc. standardized financial statements, quarterly
Creator: Listed

ZIVOOTCCIK 1101026HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$65.6k, Q3 FY2025

Operating income−$1.0m, Q3 FY2025

Net income−$1.0m, Q3 FY2025

Zivo Bioscience, Inc., income statement, quarterly
Line item	Unit	Q4 FY20222022-12-31	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30
Revenue	$k	0.0	0.0	4.1	11.8	11.8	35.7	0.0	31.5	90.0	0.0	53.4	65.6
Cost of revenue	$k	0.0	0.0	0.7	7.7	7.7	23.2	0.0	22.1	63.0	0.0	35.5	44.3
Gross profit	$k	0.0	0.0	3.3	4.1	4.1	12.5	0.0	9.5	27.0	0.0	17.9	21.3
Research and development	$k	519	402	442	221	312	313	2,252	326	243	2,769	480	203
Operating income	$k	(2,638)	(1,970)	(1,824)	(1,572)	(1,897)	(1,276)	(8,230)	(2,260)	(1,596)	(4,209)	(1,633)	(1,018)
Interest expense	$k	3.0	3.0	31.8	32.7	(43.7)	2.6	6.8	8.6	not reported	2.4	7.4	13.0
Income tax	$k	not reported	0.0	0.0	0.0	not reported	0.0	0.0	0.0	not reported	not reported	not reported	not reported
Net income	$k	(2,641)	(1,973)	(2,071)	(1,825)	(1,909)	(1,278)	(8,236)	(2,269)	(1,601)	(4,211)	(1,640)	(1,033)
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	not reported	(0.47)	(2.78)	(0.67)	not reported	(1.12)	(0.43)	(0.27)
Basic EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Balance sheet

Cash and equivalents$1.8m, FY2022

Shareholders' equity−$3.3m, Q3 FY2025

Zivo Bioscience, Inc., balance sheet, quarterly
Line item	Unit	FY20222022-12-31	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30
Cash and equivalents	$k	1,799	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current assets	$k	1,902	928	530	1,948	425	711	495	437	1,635	1,023	410	281
Total assets	$k	2,123	1,128	710	2,102	556	816	576	496	1,643	1,331	703	559
Current liabilities	$k	2,028	2,791	3,804	3,174	2,762	3,085	2,871	2,579	2,042	2,613	2,960	3,614
Total liabilities	$k	2,134	2,870	3,855	3,196	2,762	3,085	2,871	2,579	2,158	2,949	3,244	3,846
Current portion of debt	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$k	(10.6)	(1,742)	(3,145)	(1,094)	(2,206)	(2,269)	(2,296)	(2,083)	(515)	(1,617)	(2,541)	(3,287)

Cash flow

Operating cash flow−$266.6k, Q3 FY2025

Zivo Bioscience, Inc., cash flow, quarterly
Line item	Unit	Q4 FY20222022-12-31	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30
Operating cash flow	$k	(1,447)	(2,129)	(986)	(1,970)	(716)	(1,699)	(624)	(1,085)	(906)	(1,430)	(476)	(267)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)3.82m, Q3 FY2025

Zivo Bioscience, Inc., shares, quarterly
Line item	Unit	Q1 FY20142014-03-31	Q2 FY20142014-06-30	Q1 FY20152015-03-31	Q2 FY20152015-06-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30
Diluted shares (weighted)	m shares	154	125	130	130	2.7	3.0	3.4	3.8	3.8	3.8

Shares outstanding: 3.89m at Nov 9, 2025, from the cover of the 10-Q filed Nov 14, 2025.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. Listed shows no prices and gives no investment advice.